Award

Role of TGF beta family members in muscle wasting : towards innovative therapeutical approaches

Description: Context: Muscle wasting is a life-threatening syndrome involved is a wide range of cachexia-associated chronic diseases such as cardiac failure, myopathies, chronic pulmonary or kidney failure, Cushing syndrome, cancer as well as muscle aging. Despite its clinical importance, there is no approved effective chemical treatment against muscle wasting, which is usually associated with drastic loss of adipose tissue and many organ dysfunctions because of the systemic spread of these diseases. Among the signaling molecules involved in cachexia, members of the Transforming Growth Factor ß (TGFß) family (TGFß, myostatin, GDF11 and activins) are major atrophying factors. Challenge: Because of the systemic effects of TGFß ligands and the important redundancy existing among the ligands and receptors of this family, data generated so far by ligand or receptor loss or gain of function have been complex to interpret. Hypothesis: We make the hypothesis that chronic TGFß activation not only involve imbalance muscle catabolism/anabolism (excessive proteolysis leading to muscle fibers shrinkage) but also many, yet poorly explored aspects of muscle biology (energy metabolism, calcium homeostasis, regenerative capacities, muscle endocrine function, neuromuscular junction). Targeting intracellular effectors of TGFß signaling or downstream cellular consequences is then expected to limit muscle weakness associated with chronic diseases. Objectives: We will provide an unambiguous molecular description of the effects of muscle-specific chronic activation of TGFß signaling pathway on muscle mass function (WP1), muscle regenerative capacity (WP2) and the repercussion of these induced muscle alterations on whole body homeostasis (WP3). In a translational approach (WP4), we will target interesting effectors and cellular processes of muscle atrophy identified in WP 1 ,2 and 3 to initiate innovative therapeutic approaches aiming at decreasing TGFß signaling in skeletal muscle (and/or downstream targets/cellular consequences) for the prevention and the treatment of muscle atrophy. Experimental approach: We will generate muscle-specific genetically engineered mouse models, allowing inducible activation of a constitutively active TGFß receptor (ALK5) either in adult myofibers or in adult muscle stem cells. Multi-omics analyses will provide molecular signatures of TGFß-mediated muscle wasting. Further explorations will help to understand the functional impact of these deregulations, and allow the identification of new muscle atrophy biomarkers and new interesting targets to prevent muscle atrophy. Our complementary translational approach will take advantage of the possibility offered by Oncodesign (biopharmaceutical company, France) to test their new inhibitors of TGFß receptors Nanocyclix® in our paradigm. We have already generated enough preliminary results to ensure the pertinence of our models and the feasibility of the project. Consortium: Partner 1 is a specialist of skeletal muscle biology with a wide expertise ranging from molecular biology and gene expression to intracellular signaling, metabolism, and physiology of muscle cells. Partner 2 is a specialist of TGFß signaling. He has developed the molecular tools to generate the mouse models. Thanks to their longstanding expertise in drug screening, the collaboration with Oncodesign will be an asset for the targeted screening part of the project.
Amount: €459,800
Funding type: research
Funder scheme: AAPG2018
Start date: 2018-10-01
Institutions: Institut NeuroMyoGène, INSTITUT NEUROMYOGENE
Funded outputs count: 0
Funder award ID: ANR-18-CE14-0010
OpenAlex ID: G8102163265